P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011ECCO '17 Barcelona
2017
P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experienceECCO '17 Barcelona
2017
P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexateECCO '17 Barcelona
2017
P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trialECCO '17 Barcelona
2017
P419: Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's diseaseECCO '17 Barcelona
2017
P420: Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrenceECCO '17 Barcelona
2017
P421: Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysisECCO '17 Barcelona
2017
P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assayECCO '17 Barcelona
2017
P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trialECCO '17 Barcelona
2017
P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapyECCO '17 Barcelona
2017
P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort studyECCO '17 Barcelona
2017
P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patientsECCO '17 Barcelona
2017
P427: Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximabECCO '17 Barcelona
2017
P428: Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian populationECCO '17 Barcelona
2017
P429: Mucosal healing after 3 months of conventional IBD treatment: real life dataECCO '17 Barcelona
2017
P430: EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experienceECCO '17 Barcelona
2017
P431: Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab doseECCO '17 Barcelona
2017
P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort studyECCO '17 Barcelona
2017